Biopharma
29 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Dan Fisher
Scoop.it!

Genome Editing with Zinc Finger Nucleases, Medical

Genome Editing with Zinc Finger Nucleases, Medical | Biopharma | Scoop.it
This presentation is about the Genome Editing with Zinc Finger Nucleases. We Introduce the CCR5 32 Allele De Novo to Zinc Finger Nucleases. Contains two domains Nuclease domain of FokI restriction enzyme to Designed ...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Copy of HOPE, HYPE & REALITY: ZINC FINGER GENE THERAPY TO CONTROL OR CURE HIV

A video to answer your questions about a gene therapy approach to an HIV cure. On Nov 5, 2014, the defeatHIV Community Advisory Board hosted a talk with Dr. ...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

PLOS ONE: Delayed Administration of a Bio-Engineered Zinc-Finger ...

PLOS ONE: Delayed Administration of a Bio-Engineered Zinc-Finger ... | Biopharma | Scoop.it
Delayed Administration of a Bio-Engineered Zinc-Finger VEGF-A Gene Therapy Is Neuroprotective and Attenuates Allodynia Following Traumatic Spinal Cord Injury. Sarah A. Figley,. Affiliations: Department of Genetics and ...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

HIV gets the zinc finger - Virology Blog

HIV gets the zinc finger - Virology Blog | Biopharma | Scoop.it
HIV gets the zinc finger. 19 March 2014. zinc finger nuclease Because all animal viruses initiate infection by binding to a receptor on the cell surface, this step has long been considered a prime target for antiviral therapy.
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Genome Editing with Engineered Zinc Finger Proteins - Philip D. Gregory

Philip D. Gregory's talk "Genome Editing with Engineered Zinc Finger Proteins" from the First International Workshop on Mammalian Synthetic Biology, May 11-1...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

New method identifies genome-wide off-target cleavage sites of CRISPR-Cas nucleases

New method identifies genome-wide off-target cleavage sites of CRISPR-Cas nucleases | Biopharma | Scoop.it
Investigators have developed a method of detecting, across the entire genome of human cells, unwanted DNA breaks induced by use of the popular gene-editing tools called CRISPR-Cas RNA-guided nucleases.
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Amgen's new leukemia drug, Blincyto, to carry $178000 price tag - Medical Daily

Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available.
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Merck KGaA core earnings up 3 per cent on AZ takeover - Economic Times

Merck KGaA core earnings up 3 per cent on AZ takeover - Economic Times | Biopharma | Scoop.it
FRANKFURT: Germany's Merck KGaA said quarterly underlying core earnings edged up 3.1 per cent, as the recent takeover of high-tech chemicals maker AZ Electronic Materials outweighed declines in...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Genome Editing with Zinc Fingers Repairs Genetic Disease | MIT ...

Genome Editing with Zinc Fingers Repairs Genetic Disease | MIT ... | Biopharma | Scoop.it
In the new report, researchers describe treating a single infant with zinc-finger nucleases designed to repair a defective copy of an important immune system gene. The report does not look at the long term health effects for the ...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Method of the Year 2011: Gene-editing nucleases - by Nature Video

Gene-editing nucleases can make targeted and precise changes to an organism's genome. This has opened up new possibilities for the study of gene function, as...
more...
No comment yet.
Rescooped by Dan Fisher from TAL effector science
Scoop.it!

Cellectis announces the issuance by the USPTO of a patent covering a seminal nuclease-based “gene editing” method | cellectis

Cellectis announces the issuance by the USPTO of a patent covering a seminal nuclease-based “gene editing” method | cellectis | Biopharma | Scoop.it

US 8,921,332, covers “the use of a chimeric endonuclease to induce homologous recombination between a nucleic acid vector and the chromosomal DNA of the cell in vitro to modify a specific sequence”. This seminal invention is at the origin of most current nuclease-based precise gene editing technologies involving Zinc Finger Nucleases, TALEN™, Mega-TALE, BurrH Nucleases, as well as CRISPR, which all are chimeric endonucleases comprising a DNA binding sequence and a DNA cleavage domain with a recognition site of at least 12 base pairs.


Via dromius
more...
dromius's curator insight, January 10, 2015 5:54 PM

So, paired TALs with each 11 repeat arrays are exempt?

Rescooped by Dan Fisher from Pharma Biotech Industry Review (Krishan Maggon)
Scoop.it!

AstraZeneca - AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform

AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease. AstraZeneca will share cell lines and compounds with its partners and work with them to publish findings of its application of CRISPR technology in peer-reviewed journals, contributing to broader scientific progress in the field. The collaborations complement AstraZeneca’s in-house CRISPR programme and will build on the company’s ‘open innovation’ approach to research and development.

 

CRISPR (clustered regularly interspaced short palindromic repeats) is a genome-editing tool, which allows scientists to make changes in specific genes far faster and in a much more precise way than ever before. The technology has two components - a homing device to a specific section of DNA (guide-RNA) and enzymatic ‘scissors’ that cut DNA (Cas9 nuclease). In the cell nucleus, the guide-RNA sequence directs the Cas9 nuclease to cause double-stranded breaks in the target DNA sequence. By harnessing the cell’s own DNA-repair apparatus, the gene being targeted can be altered either by deleting it, adding nucleotides to it or by turning its activity on or off. In contrast to previous genome-editing techniques, such as zinc-finger nucleases and TALENs, CRISPR is easier to handle in the laboratory.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, January 29, 2015 2:57 AM

Astra Zeneca is the second pharma major after Novartis to bet on CRIPR genome editing for new drug discovery.

 

AZ R&D collaborations with

 

The Wellcome Trust Sanger Institute, Cambridge, UKThe Innovative Genomics Initiative, California

 

Thermo Fisher Scientific, Waltham, MassachusettsBroad Institute/Whitehead Institute, Cambridge, Massachusetts

 

Scooped by Dan Fisher
Scoop.it!

CRISPR Patents Spark Fight to Control Genome Editing | MIT Technology Review

CRISPR Patents Spark Fight to Control Genome Editing | MIT Technology Review | Biopharma | Scoop.it
There’s a bitter fight over the patents for CRISPR, a breakthrough new form of DNA editing.
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Mammalian cells engineered to produce longer-lived versions of therapeutic ... - Phys.Org

Mammalian cells engineered to produce longer-lived versions of therapeutic ... - Phys.Org | Biopharma | Scoop.it
Erythropoietin (EPO)—a key regulator of red blood cell production—is widely used for treating certain cancers and anemia induced by chronic kidney disease.
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

Fyodor Urnov, PhD Team leader, Sangamo Biosciences, Richmond, California

Sunday December 8: 5th Press Conference from the 55th Annual Meeting of the American Society of Hematology (ASH), 2013 Fyodor Urnov, PhD, Team leader, Sangam...
more...
No comment yet.
Scooped by Dan Fisher
Scoop.it!

CRISPR: A game-changing genetic engineering technique | Science ...

CRISPR: A game-changing genetic engineering technique | Science ... | Biopharma | Scoop.it
CRISPR is an acronym for Clustered Regularly Interspaced Short Palindromic Repeat. This name refers to the unique organization of short, partially palindromic repeated DNA sequences found in the genomes of bacteria and ...
more...
No comment yet.